

ICMJE DISCLOSURE FORM

Date: 13 September 2023

Your Name: MARTA JAZ BATISTA

Manuscript Title: Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<i>Time frame: Since the initial planning of the work</i>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
<i>Time frame: past 36 months</i>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
		GSK	
		NOVARTIS DAIICHI SANKYO	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	None	
		DAIICHI SANKYO NOVARTIS	
		ASTRA ZENCA	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
		ASTRA ZENCA DAIICHI SANKYO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
		ESNO	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

HONORARIA FROM GSK, NOVARTIS AND DAIICHI SANKYO
TRAVEL SUPPORT FROM DAIICHI-SANKYO, NOVARTIS AND ASTRA ZENCA
Leadership role at ESNO

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 13 September 2023

Your Name: JOSE RAFAEL PEREZ GARCIA

Manuscript Title: Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	
		ASTRA ZENECA, GILEAD	
		SEATTLE GENETICS, ROCHÉ, MSD	
		EISAI, DAICHI SANKYO, LILLY	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	____ None ROCHE	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

HONORARIA: ASTRA ZENECA, GILEAD, SEA TLE GENETICS, ROCHE, MSD, Eisai, DAICHI SANKYO,
LILLY
TRAVEL GRANTS: ROCHE

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 13 September 2023

Your Name: INÉS FERNANDES EIRIZ

Manuscript Title: Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<i>Time frame: Since the initial planning of the work</i>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
<i>Time frame: past 36 months</i>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
		NOVARTIS	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	None	
		DAIICHI SANKYO	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

HONORARIA: NOVARTIS
TRAVEL SUPPORT: DAIICHI SANKYO

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 13 September 2023

Your Name: TARA GON

Manuscript Title: Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<i>Time frame: Since the initial planning of the work</i>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
<i>Time frame: past 36 months</i>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
		ASTRA ZENECA	
		GILEAD NOVARTIS	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	None	
		ROCHE	
		PRIZER	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
		GILEAD	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

HONORARIA: ASTRA ZENECA, GILEAD, NOVARTIS
TRAVEL SUPPORT: ROCHE, PRIZER
ADVISORY BOARD: GILEAD

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 13 September 2023

Your Name: ANTONIO LLAMBARC

Manuscript Title: Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<i>Time frame: Since the initial planning of the work</i>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
<i>Time frame: past 36 months</i>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None LILLY, ASTRA ZENECA PETER SHARP & SHORE	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	None ROCHE PFIZER ASTRA ZENECA	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None LILLY, ROCHE PFIZER, NOVARTIS	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	None DAJ CAPITAL & INITIA RESEARCH	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None RESEARCH SUPPORT: ROCHE AGENDA, LILLY, PFIZER, NOVARTIS, MSD, GILEAD, DAIICHI SANKYO	

Please summarize the above conflict of interest in the following box:

HONORARIA: LILLY, ASTRA ZENECA, PETER SHARP & SHORE
TRAVEL SUPPORT: ROCHE, PFIZER, ASTRA ZENECA
ADVISORY BOARD: LILLY, ROCHE, PFIZER, NOVARTIS
STOCK: DAJ CAPITAL & INITIA RESEARCH
RESEARCH SUPPORT: ROCHE, AGENDA, LILLY, PFIZER, NOVARTIS, MSD, GILEAD, DAIICHI SANKYO

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 13 September 2023

Your Name: SOFA BRAGA

Manuscript Title: Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<i>Time frame: Since the initial planning of the work</i>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
<i>Time frame: past 36 months</i>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	
		DAIICHI SANIYO	COMPANY PAYMENTS
		ASTRA ZENCA	COMPANY PAYMENTS

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
		DAICHI SANUKYO	COMPANY PAYMENTS
		ASTRA ZENECA	COMPANY PAYMENTS
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	None	
		DAICHI SANUKYO	COMPANY PAYMENTS
		ASTRA ZENECA	COMPANY PAYMENTS
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

CONSULTING FEES: DAICHI SANUKYO, ASTRA ZENECA
HONORARIA: DAICHI SANUKYO, ASTRA ZENECA
TRAVEL GRANTS: DAICHI SANUKYO, ASTRA ZENECA

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 13 September 2023

Your Name: JAVIER CORTÉS

Manuscript Title: Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	
		ROCHE, CELGENE, CELLESTIA,	
		ASTRA ZENECA, SEATTLE	

GENETICS, DAICHI SANKYO,
 RYTHAC, ATHENEX, POLYPHAR,
 LILLY, NERX SHARP DORNIC, GSK,
 LEUKO, BIOASIS, CLOVIS ONCOLOGY
 BOEHRINGER INGELHEIM, ELLIPSES,
 HIBERLEK, BIOINVENT, GARDAS, GILTA D,
 NEURALIN, ZYGENIX, REVEAL GENOMICS
 EXPRESION BIOTECHNOLOGIES

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None ROCHE, NOVARTIS, CELGENE, EISAI, PRINCE, JANSSEN BIOGEN, Lilly, MERCK/SANOFI, DAICHI SANKYO, ASTRA ZENCA
6	Payment for expert testimony	<input checked="" type="checkbox"/> None
7	Support for attending meetings and/or travel	None ROCHE, NOVARTIS, EISAI, PRINCE, DAICHI SANKYO, ASTRA ZENCA, GILEAD
8	Patents planned, issued or pending	None PHARMACEUTICAL COMBINATION OF A PI3KA INHIBITOR AND A MICROTUBULE DESTABILIZING AGENT
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None
11	Stock or stock options	None MEDSIR, NEKTAR PHARMACEUTICALS, LEUKO (RELATIVE)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None
13	Other financial or non-financial interests	None RESEARCH FUNDING TO INSTITUTION: ROCHE, AMAD PHARMACEUTICALS, ASTRA ZENCA, BARALTA, GSK, SANOFI, BAYER, EISAI, FRIEDEM LA ROCHE, GUARDANT, MSD, PRINCE

20 JAVIER CORTES, ASTRYA ALEXANDRA RUIZ GIMENEZ, VIOLETA SCRBA ELIZALDE, WO 2014/199294A ISSUED HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY. ALIX PRINCE, ANTONIO LOMBARDI, JAVIER CORTES, US 2019/0338368 A1 LICENSED

Please summarize the above conflict of interest in the following box:

CONSULTING: ROCHE, CELGENE, CELLSTRA, ASTRA ZENCA, SEATTLE GENETICS, DAICHI SANKYO, ERYTHE, AETHERIX, POLYPHAR, Lilly, MSD, GSK, LEUKO, BIOSIS, CLON Oncology, BOLIVINOR Ingelheim, ELIPIS, HIZICELL, BIO MIST, GEMOAB, Gilead, Novartis, Tysabri, Arvel genomics, EXPANSION BIOTECHNOLOGIES,
HONORARIA: ROCHE, NOVARTIS, CELGENE, EISAI, PRINCE, SANOFI BIOGEN, LILLY, MSD, DAICHI SANKYO, ASTRA ZENCA
TRAVEL: ROCHE, NOVARTIS, EISAI, PRINCE, ASTRA ZENCA, DAICHI SANKYO, GILEAD
PATENTS: PHARMACEUTICAL COMBINATION OF A PI3KA INHIBITOR AND A MICROTUBULE DESTABILIZING AGENT Javier Cortes, Alejandra Ruiz Gimenez, Violeta Scrba Elizalde, WO 2014/199294A : ISSUED
HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY. ALIX PRINCE, ANTONIO LOMBARDI, JAVIER CORTES, US 2019/0338368 A1 LICENSED

STOCK: MEDSIR, NEKTAR PHARMACEUTICALS, LEUKO (RELATIVE)
RESEARCH FUNDING TO INSTITUTION: ROCHE, AMAD PHARMACEUTICALS, ASTRA ZENCA, BARALTA, GSK, SANOFI, BAYER, EISAI, FRIEDEM LA ROCHE, GUARDANT, MSD, PRINCE, PIPUR THERAPEUTICS, PURA, QUEEN MARY UNIVERSITY OF LONDON

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

20 PIPUR THERAPEUTICS, PURA, QUEEN MARY UNIVERSITY OF LONDON